Pharma Journalist -

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary…
Read More...

Astellas Pharma Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Under the terms of the agreement, the two…
Read More...

Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and…
Read More...

Sandoz announced the launch of a global roadmap to increase patient access to biologic medicines. The Act4Biosimilars Action Plan is part of the Act4Biosimilars initiative, founded by…
Read More...

Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)…
Read More...

Fresenius Kabi announced the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict. Fresenius Kabi Vasopressin Injection, USP is an…
Read More...

Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced…
Read More...

DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotides (FALCON) platform,…
Read More...

ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban…
Read More...

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose…
Read More...